{"id":"methotrexate-alone","safety":{"commonSideEffects":[{"rate":"10-30","effect":"Myelosuppression (anemia, leukopenia, thrombocytopenia)"},{"rate":"5-20","effect":"Mucositis / stomatitis"},{"rate":"10-25","effect":"Nausea and vomiting"},{"rate":"5-15","effect":"Hepatotoxicity"},{"rate":"5-10","effect":"Nephrotoxicity"},{"rate":"5-15","effect":"Alopecia"},{"rate":"5-20","effect":"Infection"},{"rate":"1-5","effect":"Pneumonitis"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Methotrexate is a folate antagonist that inhibits the enzyme dihydrofolate reductase, preventing the conversion of dihydrofolate to tetrahydrofolate. This disrupts one-carbon transfer reactions essential for nucleotide synthesis, leading to reduced DNA replication and cell division. At lower doses used in autoimmune conditions, it also has immunosuppressive and anti-inflammatory effects through multiple mechanisms including adenosine release and inhibition of T-cell activation.","oneSentence":"Methotrexate inhibits dihydrofolate reductase, blocking folate metabolism and reducing DNA synthesis and cell proliferation.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:21:01.175Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Rheumatoid arthritis"},{"name":"Acute lymphoblastic leukemia"},{"name":"Osteosarcoma"},{"name":"Breast cancer"},{"name":"Psoriasis"},{"name":"Inflammatory bowel disease"}]},"trialDetails":[{"nctId":"NCT04530565","phase":"PHASE3","title":"Testing the Use of Steroids and Tyrosine Kinase Inhibitors With Blinatumomab or Chemotherapy for Newly Diagnosed BCR-ABL-Positive Acute Lymphoblastic Leukemia in Adults","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2021-01-25","conditions":"B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1","enrollment":348},{"nctId":"NCT07493161","phase":"NA","title":"Chemotherapy With Targeted-Immunotherapy for Newly Diagnosed Ph+ ALL","status":"NOT_YET_RECRUITING","sponsor":"Institute of Hematology & Blood Diseases Hospital, China","startDate":"2026-04-01","conditions":"Ph+ ALL","enrollment":100},{"nctId":"NCT07242092","phase":"PHASE4","title":"Influence of Methotrexate Discontinuation on Immunogenicity After PCV-20 Vaccine in Patients ARDs","status":"NOT_YET_RECRUITING","sponsor":"University of Sao Paulo General Hospital","startDate":"2026-03-25","conditions":"Autoimmune Rheumatic Diseases","enrollment":192},{"nctId":"NCT03684980","phase":"EARLY_PHASE1","title":"LTA Pilot Study of Glucarpidase in Patients With Central Nervous System Lymphoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2018-11-14","conditions":"Central Nervous System Lymphoma","enrollment":58},{"nctId":"NCT07234838","phase":"","title":"Effect of Anti-Psoriatic Biologics on Risk of Anogenital Warts (CONDYPSO)","status":"RECRUITING","sponsor":"Jonathan Krygier","startDate":"2026-02-01","conditions":"Psoriasis, Condyloma Acuminata, Biotherapies","enrollment":600},{"nctId":"NCT06207123","phase":"PHASE1, PHASE2","title":"A Study to Investigate LP-118, Ponatinib, Vincristine and Dexamethasone in Relapsed/Refractory Acute Lymphoblastic Leukemia (ALL) or Lymphoblastic Lymphoma (LBL)","status":"RECRUITING","sponsor":"University of Chicago","startDate":"2024-09-13","conditions":"Acute Leukemia, Lymphoblastic Leukemia, Lymphoblastic Lymphoma","enrollment":15},{"nctId":"NCT07477691","phase":"PHASE4","title":"Immune Modulation During Palynziq® Treatment in Adults (IMPALA)","status":"NOT_YET_RECRUITING","sponsor":"BioMarin Pharmaceutical","startDate":"2026-03-31","conditions":"Phenylketonuria","enrollment":12},{"nctId":"NCT07477457","phase":"PHASE2","title":"A Study of Gefitinib, Trametinib, Disulfiram, and Sunitinib in Addition to Standard Chemotherapy in People With Osteosarcoma","status":"RECRUITING","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2026-03-11","conditions":"Osteosarcoma, Metastasis","enrollment":45},{"nctId":"NCT02114229","phase":"PHASE2","title":"Phase 2 Study of Alisertib Therapy for Rhabdoid Tumors","status":"ACTIVE_NOT_RECRUITING","sponsor":"St. Jude Children's Research Hospital","startDate":"2014-05-14","conditions":"Malignant Rhabdoid Tumor, Atypical Teratoid Rhabdoid Tumor","enrollment":125},{"nctId":"NCT04960579","phase":"PHASE1","title":"P-BCMA-ALLO1 Allogeneic CAR-T Cells in the Treatment of Subjects With Multiple Myeloma","status":"RECRUITING","sponsor":"Poseida Therapeutics, Inc.","startDate":"2022-05-05","conditions":"Multiple Myeloma","enrollment":275},{"nctId":"NCT05292664","phase":"PHASE1","title":"Venetoclax Basket Trial for High Risk Hematologic Malignancies","status":"RECRUITING","sponsor":"Andrew E. Place, MD","startDate":"2023-03-29","conditions":"Myelodysplastic Syndromes, de Novo, Myelodysplastic Syndromes, Secondary, Myelodysplastic Syndromes, Previously Treated","enrollment":30},{"nctId":"NCT07350850","phase":"PHASE2","title":"A Multicenter Two-Cohort Study of Methotrexate, Rituximab, Sintilimab and Pirtobrutinib for Treatment-Naive PCNSL vs. Real-World Investigator-Selected Treatment (Observational Cohort)","status":"RECRUITING","sponsor":"Tongji Hospital","startDate":"2025-12-25","conditions":"PCNSL, Primary Central Nervous System Lymphoma","enrollment":110},{"nctId":"NCT05581030","phase":"PHASE1","title":"CalPeg for Newly Diagnosed Acute Lymphoblastic Leukemia (ALL)","status":"RECRUITING","sponsor":"H. Lee Moffitt Cancer Center and Research Institute","startDate":"2023-05-01","conditions":"Acute Lymphoblastic Leukemia","enrollment":7},{"nctId":"NCT05316701","phase":"PHASE3","title":"Precision-T: A Randomized Study of Orca-T in Recipients Undergoing Allogeneic Transplantation for Hematologic Malignancies","status":"ACTIVE_NOT_RECRUITING","sponsor":"Orca Biosystems, Inc.","startDate":"2022-06-21","conditions":"Acute Myeloid Leukemia, Acute Lymphoid Leukemia, Mixed Phenotype Acute Leukemia","enrollment":187},{"nctId":"NCT06037811","phase":"PHASE2","title":"Early Adalimumab Induction for Immune Checkpoint Inhibitor Associated Inflammatory Arthritis","status":"RECRUITING","sponsor":"Tom Appleton","startDate":"2024-04-15","conditions":"Inflammatory Arthritis, Immune-related Adverse Event","enrollment":30},{"nctId":"NCT07446400","phase":"PHASE1","title":"A Trial to Examine the Interaction of Repinatrabit With Ethinyl Estradiol/Norethindrone, Metformin,Carbamazepine, Rosuvastatin, and Methotrexate When Administered Together","status":"NOT_YET_RECRUITING","sponsor":"Otsuka Pharmaceutical Development & Commercialization, Inc.","startDate":"2026-03-20","conditions":"Healthy Volunteers","enrollment":48},{"nctId":"NCT06289673","phase":"PHASE4","title":"Identification of Necessary Information for Treatment Induction in Newly Diagnosed Acute Lymphoblastic Leukemia/Lymphoma","status":"RECRUITING","sponsor":"St. Jude Children's Research Hospital","startDate":"2024-12-26","conditions":"Acute Lymphoblastic Leukemia, Lymphoblastic Lymphoma, Mixed Phenotype Acute Leukemia","enrollment":850},{"nctId":"NCT07443514","phase":"NA","title":"Cognitive Impairment in Patients With Diffuse Large B-Cell Lymphoma","status":"RECRUITING","sponsor":"Institute of Oncology Ljubljana","startDate":"2022-01-01","conditions":"Diffuse Large B-Cell Lymphoma","enrollment":3},{"nctId":"NCT06390319","phase":"PHASE2","title":"Adding Dasatinib Or Venetoclax To Improve Responses In Children With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia (ALL) Or Lymphoma (T-LLY) Or Mixed Phenotype Acute Leukemia (MPAL)","status":"RECRUITING","sponsor":"St. Jude Children's Research Hospital","startDate":"2024-12-27","conditions":"T-cell Acute Lymphoblastic Leukemia, T-cell Lymphoma, Mixed Phenotype Acute Leukemia","enrollment":100},{"nctId":"NCT07432815","phase":"PHASE4","title":"Treatment of Psoriasis With Depression and/or Anxiety With Methotrexate vs Combined Methotrexate and Antidepressant","status":"COMPLETED","sponsor":"Cairo University","startDate":"2025-02-01","conditions":"Depression, Anxiety, Psoriasis","enrollment":40},{"nctId":"NCT06247787","phase":"PHASE1","title":"A Study to Find the Highest Dose of Imetelstat in Combination With Fludarabine and Cytarabine for Patients With AML, MDS or JMML That Has Come Back or Does Not Respond to Therapy","status":"RECRUITING","sponsor":"Children's Oncology Group","startDate":"2025-02-04","conditions":"Recurrent Childhood Acute Myeloid Leukemia, Recurrent Childhood Myelodysplastic Syndrome, Recurrent Juvenile Myelomonocytic Leukemia","enrollment":36},{"nctId":"NCT07428551","phase":"PHASE4","title":"Comparative Study of Leflunomide Plus Methotrexate Versus Methotrexate Monotherapy in Refractory Polyarticular Juvenile Idiopathic Arthritis Patients","status":"COMPLETED","sponsor":"Bangladesh Medical University","startDate":"2024-03-01","conditions":"Juvenile Idiopathic Arthritis, Polyarticular Juvenile Idiopathic Arthritis, Refractory Polyarticular Juvenile Idiopathic Arthritis","enrollment":50},{"nctId":"NCT06960577","phase":"PHASE3","title":"Perioperative Durvalumab With Neoadjuvant ddMVAC or Gemcitabine/Cisplatin in Patients With Muscle-invasive Bladder Cancer (NIAGARA-2)","status":"RECRUITING","sponsor":"AstraZeneca","startDate":"2025-05-15","conditions":"Urinary Bladder Neoplasms, Immune Checkpoint Inhibitors, Methotrexate","enrollment":150},{"nctId":"NCT06475235","phase":"PHASE1","title":"Pembrolizumab + Chemotherapy in Newly Diagnosed PCNSL","status":"RECRUITING","sponsor":"Dana-Farber Cancer Institute","startDate":"2024-10-18","conditions":"Lymphoma, Primary Central Nervous System Lymphoma","enrollment":15},{"nctId":"NCT07410520","phase":"PHASE2","title":"PD-1 Inhibitor Combined With Rituximab, Methotrexate, and Orelabrutinib (PD-1i+RMO) for Newly Diagnosed PCNSL and SCNSL.","status":"RECRUITING","sponsor":"The First Affiliated Hospital with Nanjing Medical University","startDate":"2026-02-07","conditions":"Primary Central Nervous System Lymphoma (PCNSL), Secondary Central Nervous System Lymphoma (SCNSL)","enrollment":50},{"nctId":"NCT05535166","phase":"PHASE2","title":"Molecular and Clinical Risk-Directed Therapy for Infants and Young Children With Newly Diagnosed Medulloblastoma","status":"RECRUITING","sponsor":"St. Jude Children's Research Hospital","startDate":"2022-12-20","conditions":"Medulloblastoma","enrollment":130},{"nctId":"NCT02875314","phase":"PHASE4","title":"HeadStart4: Newly Diagnosed Children (<10 y/o) With Medulloblastoma and Other CNS Embryonal Tumors","status":"ACTIVE_NOT_RECRUITING","sponsor":"Parth Patel","startDate":"2015-09","conditions":"Medulloblastoma, Central Nervous System Embryonal Tumors","enrollment":250},{"nctId":"NCT05149365","phase":"PHASE3","title":"Sitagliptin for Prevention of aGVHD After Alternative Donor Transplation","status":"COMPLETED","sponsor":"The First Affiliated Hospital of Soochow University","startDate":"2021-12-22","conditions":"Acute-graft-versus-host Disease, Allogeneic Hematopoietic Stem Cell Transplantation","enrollment":190},{"nctId":"NCT07386587","phase":"PHASE3","title":"Methotrexate Alone vs Methotrexate + Etanercept for Minimal/Low Disease Activity in Juvenile Idiopathic Arthritis","status":"ENROLLING_BY_INVITATION","sponsor":"University of Child Health Sciences and Children's Hospital, Lahore","startDate":"2026-01-27","conditions":"Juvenile Idiopathic Arthritis","enrollment":60},{"nctId":"NCT07387926","phase":"PHASE1, PHASE2","title":"Safety and Efficacy of Asciminib in Pediatrics and Young Adults With Relapse/Refractory (r/r) Philadelphia Positive (Ph+) or ABL-class Ph-like Acute Lymphoblastic Leukemia (ALL)","status":"NOT_YET_RECRUITING","sponsor":"Novartis Pharmaceuticals","startDate":"2026-03-26","conditions":"Acute Lymphoblastic Leukemia, Leukemia, Lymphoblastic, Acute, Philadelphia-Positive, Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia","enrollment":50},{"nctId":"NCT05656248","phase":"PHASE2","title":"Study of CPX-351 (VYXEOS) in Individuals < 22 Years With Secondary Myeloid Neoplasms","status":"ACTIVE_NOT_RECRUITING","sponsor":"St. Jude Children's Research Hospital","startDate":"2023-01-17","conditions":"Myeloid Neoplasm","enrollment":25},{"nctId":"NCT02315326","phase":"PHASE1, PHASE2","title":"Bruton's Tyrosine Kinase (BTK) Inhibitor, Ibrutinib, in Patients With Newly Diagnosed or Refractory/Recurrent Primary Central Nervous System Lymphoma (PCNSL) and Refractory/Recurrent Secondary Central Nervous System Lymphoma (SCNSL)","status":"COMPLETED","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2014-12-08","conditions":"Adult Patients With Newly Diagnosed or Relapsed or Refractory Primary Central Nervous System Lymphoma (PCNSL), Or Relapsed or Refractory Secondary Central Nervous System Lymphoma (SCNSL)","enrollment":93},{"nctId":"NCT03164057","phase":"PHASE2","title":"A Trial of Epigenetic Priming in Patients With Newly Diagnosed Acute Myeloid Leukemia","status":"ACTIVE_NOT_RECRUITING","sponsor":"St. Jude Children's Research Hospital","startDate":"2017-06-15","conditions":"Acute Myeloid Leukemia, Myelodysplastic Syndromes","enrollment":206},{"nctId":"NCT07077486","phase":"PHASE4","title":"Effects of Telitacicept vs Cyclophosphamide on Lupus Related Interstitial Lung Disease","status":"RECRUITING","sponsor":"Tongji Hospital","startDate":"2025-08-25","conditions":"Lupus or SLE, Interstitial Lung Disease, Systemic Lupus Erythematosus","enrollment":100},{"nctId":"NCT04259138","phase":"PHASE4","title":"Determination of the Optimal Treatment Target in Ulcerative Colitis","status":"ACTIVE_NOT_RECRUITING","sponsor":"Alimentiv Inc.","startDate":"2020-02-18","conditions":"Colitis, Ulcerative","enrollment":672},{"nctId":"NCT06252870","phase":"PHASE2","title":"Study Testing Two Conditioning Regimen With a Single Prophylaxis of GVHD by Cyclophosphamide and Methotrexate Post-transplant in Patients Eligible for Matched-donor Allograft Transplantation","status":"RECRUITING","sponsor":"Nantes University Hospital","startDate":"2024-07-18","conditions":"Graft Versus Host Disease, Hematologic Malignancy","enrollment":82},{"nctId":"NCT07360340","phase":"","title":"Methotrexate Therapy and High-Resolution CT Chest and Spirometry Test Findings in Patients With Rheumatoid Arthritis.","status":"COMPLETED","sponsor":"Ain Shams University","startDate":"2022-12-01","conditions":"Methohexitone Pulmonary Adverse Reaction","enrollment":50},{"nctId":"NCT07352917","phase":"PHASE2","title":"Methotrexate for Severe Vulvar Lichen Sclerosus","status":"RECRUITING","sponsor":"Clinica Dermatologica Arbache ltda","startDate":"2026-01-21","conditions":"Vulvar Lichen Sclerosus","enrollment":12},{"nctId":"NCT03020030","phase":"PHASE3","title":"Treatment of Newly Diagnosed Acute Lymphoblastic Leukemia in Children and Adolescents","status":"ACTIVE_NOT_RECRUITING","sponsor":"Dana-Farber Cancer Institute","startDate":"2017-03-03","conditions":"Acute Lymphoblastic Leukemia, Pediatric","enrollment":560},{"nctId":"NCT05249426","phase":"PHASE1","title":"A Study to Test Whether Different Combinations of BI 765063, Ezabenlimab, Chemotherapy, Cetuximab, and BI 836880 Help People With Head and Neck Cancer or Liver Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Boehringer Ingelheim","startDate":"2022-04-12","conditions":"Head and Neck Squamous Cell Carcinoma (HNSCC)","enrollment":48},{"nctId":"NCT07327476","phase":"NA","title":"Effect of Oral Ice Chips to Prevent Chemotherapy-Induced Oral Mucositis in Patient With Solid Tumor Treated With 5 Fluorouracil and Methotrexate","status":"NOT_YET_RECRUITING","sponsor":"University of Health Sciences Lahore","startDate":"2026-03-01","conditions":"Chemotherapy Induced Oral Mucositis","enrollment":102},{"nctId":"NCT00602667","phase":"PHASE2","title":"Risk-Adapted Therapy for Young Children With Embryonal Brain Tumors, Choroid Plexus Carcinoma, High Grade Glioma or Ependymoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"St. Jude Children's Research Hospital","startDate":"2007-12-17","conditions":"Brain and Central Nervous System Tumors","enrollment":293},{"nctId":"NCT03121014","phase":"PHASE2","title":"Study of Intensity Modulated Total Marrow Irradiation (IM-TMI) in Addition to Fludarabine/Busulfan Conditioning for Allogeneic Transplantation in High Risk AML and Myelodysplastic Syndromes","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Illinois at Chicago","startDate":"2017-04-24","conditions":"Acute Myeloid Leukemia, Myelodysplastic Syndromes","enrollment":38},{"nctId":"NCT05814627","phase":"PHASE3","title":"Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib Compared to Subcutaneous Adalimumab in Adult Participants With Moderate to Severe Rheumatoid Arthritis","status":"ACTIVE_NOT_RECRUITING","sponsor":"AbbVie","startDate":"2023-06-15","conditions":"Rheumatoid Arthritis","enrollment":487},{"nctId":"NCT03571321","phase":"PHASE1","title":"Ruxolitinib and Chemotherapy in Adolescents and Young Adults With Ph-like Acute Lymphoblastic Leukemia","status":"RECRUITING","sponsor":"University of Chicago","startDate":"2019-05-28","conditions":"Acute Lymphoblastic Leukemia, ALL, Childhood, ALL","enrollment":15},{"nctId":"NCT06298071","phase":"PHASE1","title":"A Phase Ib Clinical Trial of Peguricase for Injection With Methotrexate in Patients With Uncontrolled Gout.","status":"RECRUITING","sponsor":"Shanghai Institute Of Biological Products","startDate":"2023-03-03","conditions":"Gout","enrollment":36},{"nctId":"NCT06001125","phase":"PHASE2","title":"Methotrexate for Immune Related Arthritis or Arthralgias (IMPACT 2.1)","status":"TERMINATED","sponsor":"AHS Cancer Control Alberta","startDate":"2024-08-12","conditions":"Arthritis, Arthralgia","enrollment":27},{"nctId":"NCT07313878","phase":"NA","title":"Evaluation of Acute and Chronic Nephrotoxicity in Acute Lymphatic Leukemia Patients Using Ultrasound Localization Microscopy","status":"RECRUITING","sponsor":"University of Erlangen-Nürnberg Medical School","startDate":"2025-11-19","conditions":"Acute Lymphoblastic Leukaemias (ALL), Long Term Follow-Up","enrollment":30},{"nctId":"NCT06528431","phase":"PHASE4","title":"Design and Evaluation of an Individualized Biodrug Tapering Strategy Based on Biodrug Dosage: the MONITORA Study","status":"RECRUITING","sponsor":"Centre Hospitalier Universitaire de Saint Etienne","startDate":"2024-12-19","conditions":"Arthritis, Rheumatoid","enrollment":180},{"nctId":"NCT03643133","phase":"PHASE2","title":"Mifamurtide Combined With Post-operative Chemotherapy for Newly Diagnosed High Risk Osteosarcoma Patients","status":"ACTIVE_NOT_RECRUITING","sponsor":"UNICANCER","startDate":"2018-10-23","conditions":"Osteosarcoma","enrollment":60},{"nctId":"NCT05457556","phase":"PHASE3","title":"Mismatched Related Donor Versus Matched Unrelated Donor Stem Cell Transplantation for Children, Adolescents, and Young Adults With Acute Leukemia or Myelodysplastic Syndrome","status":"ACTIVE_NOT_RECRUITING","sponsor":"Children's Oncology Group","startDate":"2023-03-15","conditions":"Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, Mixed Phenotype Acute Leukemia","enrollment":435},{"nctId":"NCT06387121","phase":"PHASE2","title":"Efficacy and Safety of Low-dose Chemotherapy Plus Immuno-targeted Drugs in Newly Diagnosed Adult Ph- B-ALL","status":"RECRUITING","sponsor":"Institute of Hematology & Blood Diseases Hospital, China","startDate":"2024-04-02","conditions":"Precursor Cell Lymphoblastic Leukemia-Lymphoma","enrollment":53},{"nctId":"NCT03117751","phase":"PHASE2, PHASE3","title":"Total Therapy XVII for Newly Diagnosed Patients With Acute Lymphoblastic Leukemia and Lymphoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"St. Jude Children's Research Hospital","startDate":"2017-03-29","conditions":"Acute Lymphoblastic Leukemia, Acute Lymphoblastic Lymphoma","enrollment":790},{"nctId":"NCT03739853","phase":"PHASE4","title":"Severe Psoriatic Arthritis - Early intervEntion to Control Disease: the SPEED Trial","status":"COMPLETED","sponsor":"University of Oxford","startDate":"2019-05-14","conditions":"Psoriatic Arthritis","enrollment":192},{"nctId":"NCT06186219","phase":"PHASE1","title":"Recapturing Immune Tolerance to Pegloticase for the Management of Tophaceous Gout","status":"COMPLETED","sponsor":"University of California, Los Angeles","startDate":"2024-04-10","conditions":"Tophaceous Gout","enrollment":2},{"nctId":"NCT04214626","phase":"PHASE2","title":"R-CHOP Combined With Lenalidomide in the First-line Treatment for Patients With Diffuse Large B Cell Lymphoma","status":"COMPLETED","sponsor":"Henan Cancer Hospital","startDate":"2020-01-05","conditions":"Diffuse Large B Cell Lymphoma","enrollment":60},{"nctId":"NCT06081400","phase":"NA","title":"Cryoablation Versus Medical Therapy in Desmoid Tumors Progressing After Watchful Waiting","status":"RECRUITING","sponsor":"University Hospital, Strasbourg, France","startDate":"2024-03-04","conditions":"Desmoid Tumor","enrollment":150},{"nctId":"NCT04540432","phase":"NA","title":"Evolution of Intestinal Microbiota in Patients With Juvenile Spondylarthropathy According to Typology of Treatment","status":"RECRUITING","sponsor":"Centre Hospitalier Universitaire de Nīmes","startDate":"2021-09-22","conditions":"Spondylarthropathies","enrollment":25},{"nctId":"NCT07227584","phase":"PHASE2","title":"ALL Backbone in AYAs","status":"NOT_YET_RECRUITING","sponsor":"Dana-Farber Cancer Institute","startDate":"2026-04","conditions":"Acute Lymphoblastic Leukemia, Philadelphia Chromosome-Negative Lymphoblastic Leukemia, Acute Lymphoblastic Leukemia (ALL)","enrollment":67},{"nctId":"NCT03320642","phase":"PHASE1","title":"GRAVITAS-119: Itacitinib in Combination With Calcineurin Inhibitor-Based Interventions for the Prophylaxis of Graft-Versus Host Disease","status":"TERMINATED","sponsor":"Incyte Corporation","startDate":"2018-02-27","conditions":"Hematologic Malignancies","enrollment":84},{"nctId":"NCT00136435","phase":"PHASE2","title":"A Study in Adults With Untreated Acute Lymphoblastic Leukemia","status":"COMPLETED","sponsor":"Dana-Farber Cancer Institute","startDate":"2002-06","conditions":"Acute Lymphoblastic Leukemia","enrollment":100},{"nctId":"NCT01760226","phase":"EARLY_PHASE1","title":"Dose Adjusted EPOCH-R, to Treat Mature B Cell Malignancies","status":"COMPLETED","sponsor":"Baylor College of Medicine","startDate":"2013-01","conditions":"Diffuse Large B Cell Lymphoma, Post Transplant Lymphoproliferative Disorder, Primary Mediastinal (Thymic) Large B-cell Lymphoma","enrollment":4},{"nctId":"NCT06315309","phase":"PHASE2","title":"Trial of 2 Step ATG for Acute GVHD Prevention Post Myeloablative Allogeneic Stem Cell Transplant","status":"RECRUITING","sponsor":"University of Alabama at Birmingham","startDate":"2025-04-15","conditions":"GVHD,Acute, Acute Leukemia, Myelodysplastic Syndromes","enrollment":29},{"nctId":"NCT06265584","phase":"PHASE2","title":"Trial of 2 Step ATG for Prevention of Acute GVHD Post Allogeneic Stem Cell Transplant","status":"RECRUITING","sponsor":"University of Alabama at Birmingham","startDate":"2025-04-08","conditions":"Acute Leukemia, Myelodysplastic Syndrome, Myeloproliferative Disorders","enrollment":56},{"nctId":"NCT07208890","phase":"NA","title":"Methotrexate Iontophoresis Versus Methotrexate 1% Gel on Depigmentation in Vitiligo Patients","status":"NOT_YET_RECRUITING","sponsor":"Pharos University in Alexandria","startDate":"2025-11-10","conditions":"Vitiligo - Evaluation of Methotrexate Iontophoresis and Topical Methotrexate Gel as Localized Treatment Approache","enrollment":30},{"nctId":"NCT07202819","phase":"NA","title":"Effect of Neoadjuvant Chemotherapy on MRI Accuracy Before Cystectomy","status":"RECRUITING","sponsor":"Assiut University","startDate":"2025-09-01","conditions":"Muscle Invasive Bladder Cancer","enrollment":76},{"nctId":"NCT04501614","phase":"PHASE1, PHASE2","title":"A Study of Ponatinib With Chemotherapy in Children, Teenagers, and Adults With Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia","status":"TERMINATED","sponsor":"Takeda","startDate":"2021-02-24","conditions":"Pediatric Philadelphia Chromosome-positive Acute Lymphoblastic Leukemia (Ph+ALL), Ph+ Mixed Phenotype Acute Leukemia (MPAL), Philadelphia Chromosome-Like ALL (Ph-like ALL)","enrollment":11},{"nctId":"NCT05579769","phase":"PHASE2","title":"Pediatric Study of GVHD Ppx w/o Calcineurin Inhibitors After Day60 Post First Allo HSCT for Hematological Malignancies.","status":"TERMINATED","sponsor":"St. Jude Children's Research Hospital","startDate":"2023-03-14","conditions":"Hematologic Malignancy, Myeloid Malignancy","enrollment":3},{"nctId":"NCT07196449","phase":"PHASE1","title":"Drug-Drug Interaction of Rifampicin and Cyclosporine on Methotrexate Pharmacokinetics in Healthy Subjects","status":"ACTIVE_NOT_RECRUITING","sponsor":"Seoul National University Bundang Hospital","startDate":"2025-05-14","conditions":"Drug Drug Interaction (DDI)","enrollment":12},{"nctId":"NCT04435288","phase":"PHASE3","title":"Spondyloarthritis: Inducing Drug-free Remission by Early TNF-alpha Blockade","status":"ACTIVE_NOT_RECRUITING","sponsor":"University Hospital, Ghent","startDate":"2020-08-24","conditions":"Peripheral Spondyloarthritis","enrollment":90},{"nctId":"NCT06115824","phase":"","title":"New-diagnosed PCNSL Treated With Methotrexate (MTX) and Orelabrutinib-based Regimen","status":"COMPLETED","sponsor":"Huashan Hospital","startDate":"2023-08-10","conditions":"Primary Central Nervous System Lymphoma","enrollment":136},{"nctId":"NCT05658640","phase":"PHASE1, PHASE2","title":"HEM iSMART-D: Trametinib + Dexamethasone + Chemotherapy in Children With Relapsed or Refractory Hematological Malignancies","status":"RECRUITING","sponsor":"Princess Maxima Center for Pediatric Oncology","startDate":"2023-11-14","conditions":"Acute Lymphoblastic Leukemia, in Relapse, Lymphoblastic Lymphoma (Precursor B-Lymphoblastic Lymphoma/Leukaemia) Recurrent, Lymphoblastic Lymphoma (Precursor T-Lymphoblastic Lymphoma/Leukaemia) Recurrent","enrollment":26},{"nctId":"NCT07161336","phase":"PHASE2","title":"Role of Methotrexate in Ultrasound Proven Synovitis in Primary Knee OA","status":"RECRUITING","sponsor":"Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh","startDate":"2025-07-30","conditions":"Osteo Arthritis of the Knee, Synovitis of Knee, Methotrexate","enrollment":70},{"nctId":"NCT04546399","phase":"PHASE2","title":"A Study to Compare Blinatumomab Alone to Blinatumomab With Nivolumab in Patients Diagnosed With First Relapse B-Cell Acute Lymphoblastic Leukemia (B-ALL)","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2020-12-17","conditions":"Down Syndrome, Recurrent B Acute Lymphoblastic Leukemia","enrollment":461},{"nctId":"NCT03860844","phase":"PHASE2","title":"Isatuximab in Combination With Chemotherapy in Pediatric Patients With Relapsed/Refractory Acute Lymphoblastic Leukemia or Acute Myeloid Leukemia","status":"TERMINATED","sponsor":"Sanofi","startDate":"2019-08-06","conditions":"Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia","enrollment":67},{"nctId":"NCT07142863","phase":"PHASE2","title":"Envafolimab Combined With Neoadjuvant Chemotherapy Treat Stage IIb Resectable Osteosarcoma Patients","status":"NOT_YET_RECRUITING","sponsor":"Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine","startDate":"2025-08-25","conditions":"Osteosarcoma, Neoadjuvant Therapy, Neoadjuvant Chemotherapy","enrollment":23},{"nctId":"NCT07138898","phase":"PHASE2","title":"Immunosuppressant Management in Rheumatology Patients Undergoing Elective Total Shoulder Arthroplasty","status":"NOT_YET_RECRUITING","sponsor":"NYU Langone Health","startDate":"2025-09","conditions":"Rheumatic Disease","enrollment":80},{"nctId":"NCT07021495","phase":"","title":"SKIN Disease Profiling by an Exploratory, pRospective, Biomarker Study in dermatoloGY Practice (SKINERGY)","status":"RECRUITING","sponsor":"Leiden University Medical Center","startDate":"2025-07-29","conditions":"Chronic Spontaneous Urticaria (CSU), Hidradenitis Suppurativa (HS), Psoriasis (PsO)","enrollment":840},{"nctId":"NCT04562558","phase":"NA","title":"Biweekly Actinomycin-D Treatment or Multi-day Methotrexate Protocol in Low-risk Gestational Trophoblastic Neoplasia","status":"ACTIVE_NOT_RECRUITING","sponsor":"xiang yang","startDate":"2020-09-29","conditions":"Gestational Trophoblastic Tumor, Gestational Trophoblastic Neoplasia, Stage I Gestational Trophoblastic Tumor","enrollment":228},{"nctId":"NCT07108530","phase":"PHASE2","title":"Efficacy of Integrated Induction-Consolidation Chemotherapy and Transplantation for Adult Acute Myeloid Leukemia: Multicenter Study","status":"RECRUITING","sponsor":"Shanxi Bethune Hospital","startDate":"2025-08-06","conditions":"Acute Myeloid Leukemia","enrollment":50},{"nctId":"NCT06930105","phase":"PHASE2","title":"Impact of Low-intensity Chemotherapy Combined With Short-course Blinatumomab on Allo-HSCT in Adults With Ph- B-ALL","status":"NOT_YET_RECRUITING","sponsor":"Xianmin Song, MD","startDate":"2025-09-01","conditions":"Acute Lymphoid Leukemia (ALL)","enrollment":45},{"nctId":"NCT04440267","phase":"PHASE2","title":"Efficacy of Acute Lymphoblastic Leukemia-Based Therapy in Treating Patients With Acute Leukemia of Ambiguous Lineage","status":"RECRUITING","sponsor":"Institute of Hematology & Blood Diseases Hospital, China","startDate":"2020-07-08","conditions":"Acute Leukemia of Ambiguous Lineage","enrollment":50},{"nctId":"NCT03793478","phase":"PHASE1, PHASE2","title":"Safety and Efficacy of Quizartinib in Children and Young Adults With Acute Myeloid Leukemia (AML), a Cancer of the Blood","status":"ACTIVE_NOT_RECRUITING","sponsor":"Daiichi Sankyo","startDate":"2018-08-15","conditions":"Acute Myeloid Leukemia","enrollment":65},{"nctId":"NCT06262438","phase":"PHASE2","title":"CHIP-AML22/Quizartinib: Quizartinib + Chemotherapy in Newly Diagnosed Pediatric FLT3-ITD+ and NPM1wt AML Patients","status":"RECRUITING","sponsor":"Princess Maxima Center for Pediatric Oncology","startDate":"2024-02-06","conditions":"Acute Myeloid Leukemia in Children","enrollment":60},{"nctId":"NCT06504082","phase":"NA","title":"Comparison of the Effectiveness of Single-Dose Methotrexate Protocol With Letrozole + Single-Dose Methotrexate in the Medical Treatment of Patients Diagnosed With Ectopic Pregnancy","status":"COMPLETED","sponsor":"Yuzuncu Yil University","startDate":"2021-09-20","conditions":"Ectopic Pregnancy","enrollment":60},{"nctId":"NCT07058337","phase":"NA","title":"Methotrexate in Retinal Detachment With Proliferative Vitreoretinopathy","status":"COMPLETED","sponsor":"Benha University","startDate":"2024-06-09","conditions":"Retinal Detachment","enrollment":20},{"nctId":"NCT04506554","phase":"PHASE2","title":"A Study of Risk Enabled Therapy After Neoadjuvant Immunochemotherapy for Bladder Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Fox Chase Cancer Center","startDate":"2020-12-01","conditions":"Muscle-Invasive Bladder Carcinoma","enrollment":81},{"nctId":"NCT04169828","phase":"NA","title":"The Ondansetron Premedication Trial in Juvenile Idiopathic Arthritis","status":"COMPLETED","sponsor":"University of British Columbia","startDate":"2019-08-02","conditions":"Juvenile Idiopathic Arthritis","enrollment":52},{"nctId":"NCT03817320","phase":"PHASE1, PHASE2","title":"PO Ixazomib in Combination With Chemotherapy for Childhood Relapsed or Refractory Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Therapeutic Advances in Childhood Leukemia Consortium","startDate":"2019-02-12","conditions":"ALL, Childhood, Lymphoblastic Lymphoma, Childhood, Lymphoblastic Leukemia, Acute, Childhood","enrollment":24},{"nctId":"NCT05253495","phase":"PHASE2","title":"Chemoradiotherapy With Targeted Immunotherapy in Pediatric Lymphoma","status":"RECRUITING","sponsor":"New York Medical College","startDate":"2022-02-01","conditions":"Non-hodgkin Lymphoma, Hodgkin Lymphoma","enrollment":80},{"nctId":"NCT00476190","phase":"PHASE2","title":"ALL Adult Consortium Trial: Adult ALL Trial","status":"COMPLETED","sponsor":"Dana-Farber Cancer Institute","startDate":"2007-04","conditions":"Acute Lymphoblastic Leukemia","enrollment":112},{"nctId":"NCT02303821","phase":"PHASE1","title":"Study of Carfilzomib in Combination With Induction Chemotherapy in Children With Relapsed or Refractory Acute Lymphoblastic Leukemia","status":"COMPLETED","sponsor":"Amgen","startDate":"2015-02-16","conditions":"Acute Lymphoblastic Leukemia (ALL)","enrollment":141},{"nctId":"NCT07002099","phase":"PHASE2","title":"Selinexor, High-dose Methotrexate, and Rituximab Combined With Radiotherapy for Newly Diagnosed, Transplant-ineligible Patients With Central Nervous System Lymphoma: An Open-label, Single-arm, Multicenter Phase II Study","status":"RECRUITING","sponsor":"Second Affiliated Hospital of Soochow University","startDate":"2025-06-01","conditions":"Lymphomas","enrollment":26},{"nctId":"NCT04752163","phase":"PHASE1, PHASE2","title":"DS-1594b With or Without Azacitidine, Venetoclax, or Mini-HCVD for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia or Acute Lymphoblastic Leukemia","status":"TERMINATED","sponsor":"M.D. Anderson Cancer Center","startDate":"2021-03-25","conditions":"Hematopoietic and Lymphoid Cell Neoplasm, Recurrent Acute Lymphoblastic Leukemia, Recurrent Acute Myeloid Leukemia","enrollment":17},{"nctId":"NCT05533372","phase":"PHASE1","title":"MAD Study of IA-14069","status":"RECRUITING","sponsor":"ILAb Co., Ltd.","startDate":"2022-10-10","conditions":"Healthy, Rheumatoid Arthritis","enrollment":75},{"nctId":"NCT06973811","phase":"PHASE2","title":"ZR-MTX for PIOL Phase II Trial","status":"NOT_YET_RECRUITING","sponsor":"Peking Union Medical College Hospital","startDate":"2025-05-10","conditions":"Primary Intraocular Lymphoma","enrollment":47},{"nctId":"NCT06869265","phase":"PHASE2","title":"Thiotepa Combined With Busulfan and Fludarabine Conditioning Regimen for Haploidentical Hematopoietic Stem Cell Transplantation in Elderly Patients With High-Risk Acute Myeloid Leukemia","status":"RECRUITING","sponsor":"Peking University People's Hospital","startDate":"2025-05-01","conditions":"Acute Myeloid Leukemia (AML), High Risk Acute Myeloid Leukemia(AML), Relapsed/Refractory Acute Myeloid Leukemia (AML)","enrollment":56},{"nctId":"NCT06674382","phase":"NA","title":"Haplo-HSCT for Myelofibrosis","status":"RECRUITING","sponsor":"Peking University People's Hospital","startDate":"2024-01-01","conditions":"Myelofibrosis","enrollment":39},{"nctId":"NCT01184885","phase":"EARLY_PHASE1","title":"A Pilot Study to Determine the Safety and Tolerability of Sirolimus Given With Hyper-CVAD Chemotherapy","status":"COMPLETED","sponsor":"Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University","startDate":"2010-07","conditions":"Lymphoid Malignancies (New or Relapsed), Acute Lymphoblastic Leukemia, Burkitt Lymphoma","enrollment":7},{"nctId":"NCT06946407","phase":"NA","title":"Rituximab, Methotrexate, and Tepadina Induction Followed by Etoposide and Cytarabine Consolidation in Primary Central Nervous System Lymphoma","status":"RECRUITING","sponsor":"FengYan Jin","startDate":"2022-12-02","conditions":"Primary Central Nervous System Lymphoma (PCNSL), CNS Lymphoma Treatment","enrollment":41}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":411,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["MTX: Trexan or Methotrexate"],"phase":"phase_3","status":"active","brandName":"Methotrexate alone","genericName":"Methotrexate alone","companyName":"Helsinki University Central Hospital","companyId":"helsinki-university-central-hospital","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Methotrexate inhibits dihydrofolate reductase, blocking folate metabolism and reducing DNA synthesis and cell proliferation. Used for Rheumatoid arthritis, Acute lymphoblastic leukemia, Osteosarcoma.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}